Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human Phospholamban Antibodies:
anti-Mouse (Murine) Phospholamban Antibodies:
anti-Rat (Rattus) Phospholamban Antibodies:
Go to our pre-filtered search.
Chicken Monoclonal Phospholamban Primary Antibody for ICC, IF - ABIN152737
Liu, Hu, Wang, Xu, Wang, Gong, Mansoor, Lee, Hou, Zeng, Zhang, Jerosch-Herold, Guo, Bache, Zhang: Autologous stem cell transplantation for myocardial repair. in American journal of physiology. Heart and circulatory physiology 2004
Show all 5 references for ABIN152737
Human Polyclonal Phospholamban Primary Antibody for WB - ABIN1882182
Fujii, Zarain-Herzberg, Willard, Tada, MacLennan: Structure of the rabbit phospholamban gene, cloning of the human cDNA, and assignment of the gene to human chromosome 6. in The Journal of biological chemistry 1991
Show all 4 references for ABIN1882182
Cow (Bovine) Polyclonal Phospholamban Primary Antibody for EIA, WB - ABIN499141
Møller, Pham, Gustafsson, Hedley, Ersbøll, Bundgaard, Andersen, Torp-Pedersen, Køber, Christiansen: The role of Lamin A/C mutations in Danish patients with idiopathic dilated cardiomyopathy. in European journal of heart failure 2009
LMOD1 (show LMOD1 Antibodies), SYNPO2 (show SYNPO2 Antibodies), PDLIM7 (show PDLIM7 Antibodies), PLN, and SYNM (show SYNM Antibodies) down-regulation reflect the altered phenotype of smooth muscle cells in vascular disease and could be early sensitive markers of SMC (show DYM Antibodies) dedifferentiation.
microRNAs (miRNAs) 1 and 21 bind PLN strongly and relieve PLN inhibition of SERCA (show ATP2A3 Antibodies) to a greater extent than a similar length random sequence RNA mixture.
Data suggest phospholamban (PLN) gene is a rare cause of cardiomyopathy in African patients.
Phospholamban and sarcolipin (show SLN Antibodies) are membrane proteins that differentially regulate SERCA (show ATP2A3 Antibodies) function. (Review)
PLN may be a key molecular player in rigid substrate-induced cellular hypertrophy in eosinophilic esophagitis.
These data suggest that PLN is, at least partially, oligo-ubiquitinated at Lys (show LYZ Antibodies)(3) and degraded through Ser (show SIGLEC1 Antibodies)(16)-phosphorylation-mediated poly-ubiquitination during heart failure.
hereditary mutants of phospholamban are associated with heart failure [review]
PLN pentamers reduce phosphorylation of monomers at baseline and delay monomer phosphorylation upon PKA stimulation leading to increased interaction of PLN monomers with SERCA2a (show ATP2A2 Antibodies).
Phospholamban R14del mutation carriers are at high risk for malignant ventricular arrhythmias and end-stage heart failure, with left ventricular ejection fraction <45% and sustained or nonsustained ventricular tachycardia as independent risk factors.
Although SLN (show SLN Antibodies) and PLB binding to SERCA (show ATP2A3 Antibodies) have different functional outcomes on the coupling efficiency of SERCA (show ATP2A3 Antibodies), both proteins decrease the apparent Ca(2 (show CA2 Antibodies)+) affinity of the pump, suggesting that SLN (show SLN Antibodies) and PLB inhibit SERCA (show ATP2A3 Antibodies) by using a similar mechanism.
Phosphorylation of PLB induces spatial rearrangements between the N- and P-domain elements of proximal Ca-ATPase (show CA-P60A Antibodies).
Molecular dynamics simulations of phospholamban in solution and in membrane bilayer show two main features: the presence of two well-defined helical domains at the N- and C-termini, and large-amplitude rigid-body motions of these domains.
The expression of SLN (show SLN Antibodies) and PLB mRNA and protein relative to SERCA1 (show ATP2A1 Antibodies) or SERCA2 (show ATP2A2 Antibodies) was assessed in ventricle, atrium, and skeltal msucle of mouse, rat, rabbit and pig.
the commercially available overexpressing phospholamban mouse phenotypically resembles human Centronuclear myopathy and could be used as a model to test potential mechanisms and therapeutic strategies.
Cardioprotective effects of H2S are mediated through acGMP/PKG (show PRKG1 Antibodies)/phospholamban pathway.
combined deletion of Phd2 (show EGLN1 Antibodies) and Phd3 (show EGLN3 Antibodies) dramatically decreased expression of phospholamban (PLN), resulted in sustained activation of calcium/calmodulin (show Calm2 Antibodies)-activated kinase II (CaMKII (show CAMK2G Antibodies)), and sensitized mice to chronic beta-adrenergic stress-induced myocardial injury
the N termini of SLN (show SLN Antibodies) and PLB influence their respective unique functions
CaMKII (show CAMK2G Antibodies)-dependent increase in PLN phosphorylation during reperfusion opposes rather than contributes to ischemia/reperfusion damage.
TNAP (show ALPL Antibodies) plays a role in governing the phosphorylation status of phospholamban in the sarcoplasmic reticulum.
SLN (show SLN Antibodies) and PLN are co-expressed in most fibers, which suggests that super-inhibition of SERCAs may be physiologically important in the regulation of intracellular Ca2 (show CA2 Antibodies)+ in human skeletal muscle.
Epac1 (show RAPGEF3 Antibodies) KO exhibited decreased cardiac contractility with reduced phospholamban (PLN) phosphorylation at serine-16, the major PKA-mediated phosphorylation site.
Acute expression of R9C mutation of phospholamban in cardiomyocytes was positively inotropic/lusitropic.
Ca(2 (show CA2 Antibodies)+) and PLB phosphorylation relieve SERCA (show ATP2A3 Antibodies)-PLB inhibition by distinct mechanisms, but both are achieved primarily by structural changes within the SERCA (show ATP2A3 Antibodies)-PLB complex, not by dissociation of that complex.
Phosphorylated phospholamban stabilizes a unique conformation of SERCA (show ATP2A3 Antibodies) that is characterized by a compact architecture.
Data suggest that phospholamban PLN's conformational equilibrium is central to maintain sarcoplasmic reticulum Ca(2+)-ATPase (show CA-P60A Antibodies) SERCA's apparent Ca(2 (show CA2 Antibodies)+) affinity within a physiological window.
demonstrate that the role of Arg(9) in phospholamban function is multifaceted: it is important for inhibition of SERCA (show ATP2A3 Antibodies), it increases the efficiency of phosphorylation, and it is critical for protein kinase A recognition
The interaction energies between the N-terminal helix of phospholamban and different POPC lipid/cholesterol bilayers quantitatively confirm its stronger interaction with a higher cholesterol-containing membrane.
The lipid bilayer composition influences the regulation of SERCA (show ATP2A3 Antibodies) by PLN.
Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transport.
The protein encoded by this gene is found as a pentamer and is a major substrate for the cAMP-dependent protein kinase in cardiac muscle. The encoded protein is an inhibitor of cardiac muscle sarcoplasmic reticulum Ca(2+)-ATPase in the unphosphorylated state, but inhibition is relieved upon phosphorylation of the protein. The subsequent activation of the Ca(2+) pump leads to enhanced muscle relaxation rates, thereby contributing to the inotropic response elicited in heart by beta-agonists. The encoded protein is a key regulator of cardiac diastolic function. Mutations in this gene are a cause of inherited human dilated cardiomyopathy with refractory congestive heart failure.
, cardiac phospholamban